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Summary 
Herein, we demonstrate that purlfied Stat1 binds to 
its tyroslne-phosphorylated docking site on the IFNy 
receptor a chain in a direct, specffic, and reversible 
manner. Using surface plasmon resonance, we deter- 
mine the affinity (KD = 137 nM) and specffktty of the 
interaction and define the mlnimum afflnftY needed for 
receptor-mediated Stat1 activation. In addition, we 
quantltate the relative ability of purified Stat1 to inter- 
act with tyrosine-phosphorylated bindlng sites on 
other Stat proteins. Finally, we describe experlments 
that imply that the unidirectional release of activated 
Stat1 from the IFNy receptor reflects the preference of 
free tyrosine-phosphorylated Stat1 monomers to form 
high avidity reciprocal homodimers rather than reas- 
sociating with the receptor bindlng site. Our results 
demonstrate that IFNy-induced Stat1 activation is an 
ordered and affinitydriven process and we propose 
that this process may serve as a paradigm for Stat 
activation by other cytoklne receptors. 
Introduction 
Interferon-y (IFNy) is an immunomodulatory cytokine that 
induces its pleiotropic effects on cells following interaction 
with a species-specific receptor expressed on cell sur- 
faces (Farrar and Schreiber, 1993). Functionally active 
IFNy receptors consist of two species-matched polypep- 
tide chains: a 90 kDa a chain that is necessary and suffi- 
cient for ligand binding and necessary but not sufficient 
for signal transduction, and a 62 kDa j3 chain that is re- 
quired for signal transduction (Schreiber and Aguet, 1994). 
Work from several laboratories has shown that IFNy sig- 
naling involves the participation of specific members of 
the Janus kinase-signal transducers and activators of 
transcription (Jak-Stat) signaling pathway, including the 
tyrosine kinases Jak-1 and Jak-2 and the latent cytosolic 
SH2 domain containing transcription factor Stat1 (Darnell 
et al., 1994; Miiller et al., 1993; Watling et al., 1993; Fu, 
1992; Shuai et al., 1992). We have recently shown that 
IFNy induces the rapid and reversible phosphorylation of 
the only functionally critical tyrosine residue at position 
440 in the intracellular domain of the human IFNy receptor 
a chain (Greenlund et al., 1994). Using a cell-free assay 
system, we showed that a specific IFNy receptor a chain 
intracellular domain peptide corresponding to residues 
436-444 that contained a phosphotyrosine residue for 
Y440 inhibited ligand-induced tyrosine phosphorylation 
and activation of Stat1 . Moreover, a biotinylated 436447 
phosphopeptide (but not biotinylated nonphosphorylated 
peptide nor biotinylated irrelevant phosphopeptides) spe- 
cifically precipitated Stat1 (and not Stat2) from cellular 
homogenates. Based on theseobservations, we proposed 
that the liganddependent phosphorylation of Y440 in the 
human IFNy receptor a chain intracellular domain creates 
a docking site on the receptor for Stat1 and thereby pro- 
vides the mechanism that couples the activated receptor 
to its signal transduction system (Greenlund et al., 1994). 
The .aforementioned studies were conducted in crude 
cell homogenates. Therefore, it was not possible to deter- 
mine whether Stat1 interaction with its phosphorylated re- 
ceptor docking site was direct or mediated via an adapter 
protein. In the current report, we demonstrate that purified 
recombinant Stat1 associates directly with the phosphory- 
lated Y440-containing sequence of the IFNy receptor a 
chain and quantitate the affinity of the interaction by sur- 
face plasmon resonance. Using a hamster monoclonal 
antibody (MAb) specific for the Stat1 SH2 domain, we 
show that interaction of Stat1 with the phosphorylated 
IFNy receptor a chain occurs through the Stat1 SH2 do- 
main. Finally, using phosphotyrosine containing peptides 
derived from proteins to which Stat1 binds, a range of 
affinities is determined that explains and predicts the or- 
dered interactions that occur between Stat1 and its spe- 
cific ligands. 
Results 
Generation and Characterization of Purlfied 
Recombinant Human Stat1 
SDS-PAGE analysis of the purified His-tagged recombi- 
nant Stat1 preparations followed by protein staining re- 
vealed that the preparations contained a major protein 
species displaying an M, of 90 kDa and a minor component 
(2.5%) of M, 65 kDa (Figure 1). Western blot analysis per- 
formed with polyclonal antisera raised against the amino 
terminal 65 aa of Stat1 showed that both proteins were 
Stat1 related. When blots were developed with antisera 
specific for the Stat1 SH2 domain or the carboxy-terminal 
36 aa of Statl, only the 90 kDa component was recog- 
nized. Thus, the lower molecular mass band represented 
a truncated Stat1 polypeptide lacking the SH2 domain and 
carboxyl tail. 
To document that the purified protein was indeed Stati, 
we monitored the ability of the purified Stat1 preparation 
to bind DNA following exposure to purified Jak-1 kinase 
and ATP (Figure 1B). Whereas no DNA binding was ob- 
served in the untreated purified Stat1 preparation, strong 
binding activity was expressed in Stat1 preparations fol- 
lowing in vitro tyrosine phosphorylation. The gel shift com- 
plex formed with purified proteins migrated in a manner 
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Figure 1. Analysis of Purified Recombinant Human Stat1 
(A) SDS-PAGE analysis of purified recombinant human Statl. Purified 
Stat1 (2.5 ug) was subjected to SDS-PAGE on a 9% polyacrylamide 
gel. Subsequent to electrophoresis, the protein was visualized using 
Coomassie brilliant blue stain. Purified recombinant human Stat1 (100 
ng) was also subjected to SDS-PAGE and electrophoretically trans- 
ferred to nitrocellulose followed by Western blot analysis using rabbit 
antisera against the amino(N) terminus, SH2 domain, or the carboxy 
(C) terminus of human Statl. 
(8) Expression of DNA binding activity by purified Stat1 following incu- 
bation with purified Jak-I and ATP. Reaction mixtures containing 1 
ug purified Statl, 1 pg purified Jak-1 tyrosine kinase, or both, were 
incubated at 23OC for 30 min in kinase reaction buffer in the absence 
or presence of 200 uM ATP. The formation of a Stat1 complex capable 
of binding DNA was monitored by subjecting 50% of each reaction 
mixture to EMSA using a slP-labeled oligonucleotide probe derived 
from the GRR of the FnRl gene. Nuclear extracts (24 ug) derived 
from IFNy-treated Cola-205 cells were also subjected to EMSA. 
that was similar to that of the natural Statlcontaining gel 
shift complex generated in IFNy-treated Colo-205 cells. 
Moreover, polyclonal antiserum specific for the Stat1 car- 
boxy-terminal 36 aa was able to supershift either DNA 
binding complex (data not shown). Thus, the purified prep- 
aration contained a protein that was antigenically and 
functionally identical with the natural Stat1 molecule. 
Purified Stat1 Interacts Directly with the 
IFNy Receptor a Chain-Derived 
436-447 Phosphopeptlde 
The ability of highly purified Stat1 to interact with the phos- 
phorylated YucDKPHou sequence of the IFNy receptor a 
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Figure 2. Interaction Between Stat1 and its Tyrosine Phosphorylated 
Docking Site on the IFNy Receptor Intracellular Domain Is Direct and 
Mediated by the Stat1 SH2 Domain 
(A) Direct precipitation of purified Stat1 with the IFNy receptor a chain- 
derived Y440 containing phosphopeptide. Purified Stat1 (10 nM) was 
incubated with 100 nM of either biotinylated nonphosphorytated 435- 
447 peptide (TSFGYDKPHVLV), biotinylated tyrosine-phosphoryfated 
436-447 peptide (TSFGY-PC,DKPHVLV), or biitinyfated tyrosine- 
phosphorylated 459-459 peptide (SLIGY-POIRPTEDSK). Biotinylated 
peptides were precipitated with immobilized streptavidin and precipi- 
tates examined by SDS-PAGE and Statl-specific Western blotting. 
In addition, 250 ng of purified Stat1 was subjected directly to SDS- 
PAGE and Western blot analysis. 
(B) Purified Stat1 (IO nM) was incubated in the absence of MAb or 
the presence of 100, 30, 10, or 3 ug of the anti-Stat1 SH2 domain- 
specific MAb ATO-2F5 or 100 ug of irrelevant H22 MAb. Stat1 (10 nM) 
was also incubated with 15 ul of either normal hamster sera (normal 
sera) or rabbit antiserum specific for the carboxy-terminal 39 aa of the 
Stat1 polypeptide (RaStatl C). After a 5 hr incubation, the biotinytated 
IFNT receptor-derived 439-447 phosphopeptide was added to the re- 
actions at a final concentratttn of 33 nM. Peptldes were precipitated 
and precipitates analyzed for the presence of Stat1 as in (A). 
chain was determined by coprecipitation analysis using 
purified biotinylated forms of receptor-derived 12 aa pep 
tides (Figure 2A). Stat1 was not coprecipitated with either 
biotinylated nonphosphorylated 436-447 peptide (Figure 
2A, lane 1) or biotinylated irrelevant phosphotyrosine con- 
taining 456-469 peptide (lane 3). In contrast, purified Stat1 
was coprecipitated with biotinylated 436-447 peptide con- 
taining phosphotyrosine at position 440 (Figure 2A, lane 
2). Coprecipitation was highly efficient, since at least 33% 
of the purified Stat1 was precipitated as determined by 
comparison of band intensity with a known amount of the 
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Figure 3. BlAcore Biosensor Analysis of Stat1 Binding to the IFNy 
Receptor a Chain-Derived 435-447 Phosphopeptide 
(A) Purified Stat1 at concentrations of 35 nM, 50 nM, 75 nM, 100 nM, 
150 nM, or 200 nM was injected over a streptavidin sensorchip surface 
to which the biotinylated IFNy receptor-derived 435-447 phosphopep 
tide was immobilized as described in Experimental Procedures. The 
series of sensograms presented is representative of six independent 
experiments. 
(B) Stat1 steady-state equilibrium binding responses determined from 
(A) were subjected to Scatchard analysis and the Ko of the Statl- 
IFNy receptor phosphopeptide interaotion was determined. The plot 
represents R/C (steady-state equilibrium response [R&tat1 ooncen- 
tration [nM]) versus R (steady-state equilibrium response [F&j). 
(C) Purified Stat1 (0.5 uh4) was incubated in the absence or presence 
of the soluble IFNy receptor-derived 435-446.phosphopsptide at con- 
centrations of 0.016.0&3,0.4, 2.0, or 10 uM for 30 min at 10% Reao 
tion mixtures were then injected over a sensorchip surface to which the 
biotinylated IFNy receptor 435-447 phosphopeptide was immobilized. 
The initial binding rate of these mixtures was determined and the KD 
of the interaction of Stat1 with soluble IFNT receptor phosphopeptide 
was calculated as described in Experimental Procedures. The senso- 
grams presented are representative of six independent experiments. 
entire purified preparation that was subjected directly to 
SDS-PAGE and Western blot analysis (Figure 2A, lane 
4). Thus, Stat1 interacts directly with its phosphorylated 
docking site on the IFNy receptor a chain. 
To determine the region of Stat1 involved in phospho- 
peptide binding, we monitored the ability of antibodiesspe- 
cific for distinct topographical regions of Stat1 to block 
coprecipitation of the protein with biotinylated phosphory- 
lated IFNy receptor a chain 438-447 peptide. Coprecipita- 
tion of Stat1 was inhibited in a dose-dependent fashion 
by a hamster MAb ATC-2F5 specific for the Stat1 SH2 
domain (Figure 26). In contrast, coprecipitation of Stat1 
was not inhibited by either irrelevant MAb (H22, anti- 
murine IFNy), normal hamster serum, polyclonal antise- 
rum specific for the Stat1 carboxyl terminus (RaStatlC) 
or, in another experiment, polyclonal antiserum specific 
for the Stat1 amino terminus (data not shown). These re- 
sults suggest that the interaction between Stat1 and the 
phosphorylated IFNy receptor sequence is mediated by 
the Stat1 SH2 domain. This concept is supported by the 
observation that a mutant Stat1 protein containing a Lys 
substitution for the functionally critical R603 residue within 
the SH2 domain was unable to bind the phosphorylated 
receptor peptide (data not shown). 
BlAcom Biosensor Analysis of St&l Blndlng 
to the IFNy Receptor-Derived 
436-447 Phosphopeptide 
Based on the observation that Stat1 interacted directly 
with its phosphorylated IFNy receptor docking site, we 
determined the affinity of the interaction using surface 
plasmon resonance. Binding of Stat1 to a sensorchip 
coated with biotinylated phosphorylated 438-447 peptide 
was monitored over a Stat1 concentration range of 38- 
200 nM (Figure 3A). On the basis of six independent deter- 
minations, the kinetic on and off rate constants were deter- 
mined to be 8.8 f 0.9 x l(r S-M-~ and 5.7 f 1.6 x 
1O-3 s-l, respectively, leading to a calculated equilibrium 
dissociation constant of 88 nM. However, because the 
dissociation portion of the binding reaction was influenced 
by rebinding of Stat1 to surface-bound phosphopeptide, 
we empirically determined the KD by conducting Scatchard 
analysis of the steady-state equilibrium binding (Figure 
38). Based on six independent experiments, the KD of the 
interaction was calculated to be 137 f 26 nM. To confirm 
this value, the solution affinity of Statl-phosphopeptide 
complexes was determined by incubating Stat1 with con- 
centrations of soluble phosphopeptide ranging from 
0.018-10 uM and quantitating the initial binding rate of 
these mixtures to a phosphopeptide-coated sensorchip 
surface (Figure 3C). The KO derived from this analysis was 
138 f 39 nM, which is in good agreement with the value 
determined by Scatchard analysis. 
Stat1 binding was specific. Whereas Stat1 bound to sur- 
faces coated with biotinylated 438-447 phosphopeptide 
(825 response units [RU]), no binding of Stat1 was ob- 
served to surfaces coated with either nonphosphorylated 
438-447 peptide (2 RU) or irrelevant 458-469 phospho- 
peptide (0 RU). In addition, StatP, a Stat family member 
that is involved in IFNa signal transduction but not IFNy 
signaling did not bind to the IFNy receptor-derived 436 
447 phosphopeptide (2 RU). 
Positions +l and +4 Relative to the Phosphotyrosine 
Residue Determine the Affinity of 
Stat1 -Phoephopeptlde Association 
Our previous structure-function workon the IFNy receptor 
established that Ala substitution of any one of three IFNy 
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Figure 4. BlAcore Competition Binding Assay to Define the Relative 
Importance of IFNy Receptor a Chain Amino Acids in Mediating Stat1 
Docking 
Purified Stat1 (0.5 NM) was incubated for at least 30 min with IFNy 
receptor a chain-derived peptides at concentrations of 0.016. 0.06, 
0.4, 2.0, 10, 50, or 250 PM prior to being injected over a sensorchip 
surface containing immobilized IFNr receptor a chain-derived biitinyl- 
ated 436-447 phosphopeptide. The tyrosine-phosphorylated peptides 
corresponded to residues 436-446 (hgRY440-PO,, 11 -mer, [A and BD, 
440-444 (minimal Cmer. [Au, 458-489 (hgRY462-PO,, irrelevant, [Al), 
or 4364@ derivatives (B) containing Ala substitutions for D441 (DA 
mutant), K442 (KA mutant), P443 (PA mutant), and H444 (HA mutant). 
The nonphosphotylated peptideamtalned residues436-M (hgRY440, 
]A]). To avoid bulk refractive index changes due to differences between 
the injected solution and the elution buffer, the resonance signal 20 
s after the end of the injection was monitored. Binding was calculated 
as the percentage of the total Stat1 binding in the absence of cornpet- 
ing peptide. This data represents the mean and standard deviation of 
at least three independent experiments for each psptide except for 
the nonphosphorylated IFNy receptor Y44O-containing peptide, which 
was used as either a 5-mer (data not shown) or a g-mer (hgRY440, 
Smer) in lwo separate experiments. The peptide sequences are repre- 
sented in Table 1. 
receptor a chain amino acids (Y440, D441, or H444) pro- 
duced an IFNy receptor that was unable to support ligand- 
induced biologic responses in cells (Farrar et al., 1992). 
Moreover, we subsequently showed that a receptor- 
derived phosphopeptide encompassing amino acids 436 
447 blocked Stat1 recruitment and activation by ligated 
IFNy receptors in cell homogenates, while a mutant phos- 
phopeptide containing Ala substitutions for both D441 and 
H444 did not (Greenlund et al., 1994). This data unequivo- 
cally confirmed the biologic importance of these three 
amino acids. To define the molecular basis of these obser- 
vations, we quantitated the ability of nonbiotinylated pep 
tides derived from the Y440 region of wild-type and mutant 
IFNy receptors to inhibit binding of purified Stat1 to a sen- 
Table 1. Relative Slat1 Affinities for Sites on Natural and Mutant 
TyrosinsPhosphorylated Stat1 Ligands 
Peptide Peptidesequence IDm (VW 
hgR Y462-PO, SL I GYP RPTEDSK >250 
hgR Y440 TSFGY DKPH- - >260 
hgR Y440-PO, TSFGYP DKPHVL 0.56 
hgR Y44O-P0, Lmer ----yPDKPH-- 1.1 
hgR DA mutant TSFGYP AKPHVL 22 
hgR KA mutant TSFGYP DAPHVL 0.50 
hgR PA mutant TSFGYPDQHVL 1.1 
hgR HA mutant TSFGYP DKP&‘L 14 
Stat1 Y701-PO, KGTGr I KTEL I 60 
Stat1 ID/EH mutant KGTGYP EKTHL I 4.3 
stat2 YWSPO, ERRKYP LKHRL I 7.5 
stat3 Y705PO. SAAPYp LKTKF I 33 
Stat4 Y694-PO, GDKGYP VPSVF I 60 
stat5 Y694+0, AVDGY p VKPQ I K 300 
stat6 Y641 -PO, DGRGYp VPAT I K 32 
ID, (rM)values wereobtained for phosphopeptides by inhibiting Stat1 
(0.5 PM) binding to immobilized IFN rece@or a chain 43s-447 phos- 
phopeptide with soluble phosphopeptids derivatives using a BlAcore 
competition assay. 
sorchip surface coated with biotinylated phosphorylated 
IFNy receptor 436-447 peptide (Figure 4A; Table 1). No 
significant inhibition was obsetved with either the non- 
phosphorylated 436-444 peptide (hgRY440 Qmer) or the 
phosphorylated 456469 peptide (hgRY462-PO, irrele- 
vant) when used at concentrations up to 250 PM. In con- 
trast, soluble phosphorylated 436-446 peptide efficiently 
blocked binding of 0.5 PM Stat1 to the 436-447 phospho- 
peptide-coated surface and displayed an IDso of 0.55 pM 
(hgRY440-PO4 1 1-mer). Comparable inhibition was also 
observed with a minimal phosphopeptide consisting only 
of phosphotyrosineuo-Asp-Lys-Pro-His,,, (minimal 5+ner, 
IDS0 = 1 .l PM). Therefore, this five amino acid sequence 
constitutes a major portion of the receptor docking site for 
Statl. 
We next examined the extent to which the four amino 
acids downstream of the phosphorylated Y440 residue 
contributed to the binding affinity. For this purpose, we 
used a series of peptides that contained Ala substitutions 
for amino acids 441-444. This approach was specifically 
chosen since Alascanning is an accepted method to mea- 
sure the contribution of amino acid side chains to protein- 
protein interactions and we had already established the 
biological consequences of the substitutions on receptor 
function (Farrar et al., 1992). Ala substitution of either K442 
or P443 did not effect the ability of Stat1 to bind the re- 
sulting phosphopeptide (Figure 48, KA mutant and PA 
mutant, IDso = 0.50 pM and 1 .l HIM, respectively). In con- 
trast, Stat1 bound to phosphopeptides containing Ala sub- 
stitutions for either D441 (DA mutant) or H444 (HA mutant) 
with 40- or 25-fold lower affinities, respectively. Thus, a 
25- to 40-fold reduction in affinity of Statl-IFNr receptor 
interaction correlates with the loss of IFNydependent sig 
naling observed with Ala-substituted receptor mutants in 
intact cells (Farrar et al., 1992). These results suggest that 
the interaction between Stat1 and its docking site on the 
IFNy receptor intracellular domain is critically dependent 
on three receptor contact residues: phosphotyrosine and 
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two amino acids at positions +l and +4 relative to the 
phosphotyrosine. 
Stat1 Binds Phosphopeptides Derived 
from Stat Proteins 
Following interaction with tyrosine-phosphorylated se- 
quences within the intracellular domains of ligated cyto- 
kine receptors, Stat proteins become themselves tyrosine 
phosphorylated and form homo- or heterodimeric Stat 
complexes (Fu and Zhang, 1993; Greenlund et al., 1994; 
Shuai et al., 1992, 1993a; Schindler et al., 1992b; Zhong 
et al., 1994; Akira et al., 1994; Hou et al., 1994; Wakao 
et al., 1994; lmprota et al., 1994). Stat1 dimerization has 
been the best studied to date, and it is known that phos- 
phorylation of Y701 is the event that leads to Stat1 homodi- 
mer formation (Shuai et al., 1993a, 1994). We therefore 
utilized the BlAcore competition assay to quantitate the 
interaction of Stat1 with phosphotyrosine containing pep- 
tides derived from each of the six recognized Stat family 
members that included the tyrosine residue within each 
Stat that is homologous to either Stat1 Y701 (Stat3 and 
Stat4) or Stat2 Y690 (Stat5 and Stats) (Figure 5, Table 
l).Binding of purified Stat1 to the IFNy receptor phospho- 
peptide-coated sensorchip was inhibited by the Stat1 
phosphopeptide in a dose-dependent manner. The inhibi- 
tory activity of the Stat1 phosphopeptide (IDso = 60 pM) 
was 110 times lower than that of the IFNy receptor phos- 
phopeptide (IDso = 0.55 PM). However, if the amino acids 
in the Stat1 phosphopeptide at positions +1 and +4 rela- 
tive to the phosphotyrosine (he and Glu) were replaced 
by the corresponding IFNy receptor amino acids (Asp and 
His, respectively), the inhibitory activity of the resulting 
phosphopeptide now approached that of the phosphory- 
lated receptor sequence (IDso = 4.3 PM; Table 1). 
Stat1 bound to the Stat2 phosphopeptide with an affinity 
that was intermediate between the IFNy receptor and 
Figure 5. BlAcore Stat1 Competition Binding 
Assay with Stat-Derived Phosphopeptides 
Purified human Stat1 (0.5 CM) was incubated 
for at least 30 min with peptide concentrations 
of0.016,0.06,0.4,2.0,10,50,or250pMbsfore 
being injected over a sensorchip surface to 
which the IFW receptor a chain-derived biotin- 
ylated 436-447 phosphopeptide was immobi- 
lized. The tyrosinephosphorytated peptides 
used corresponded to residues 897-707 of hu- 
man Statl, 666-696 of human Stat2,701-711 
of human Stat3,690-700 of murine Stat4, WO- 
700 of ovine Stat5, 637-647 of human Stats. 
The IFNr receptor a chain-derived tyrosinb 
phosphoryfated peptide corresponded to resi- 
dues 436446 (hgRY44gPO.). To calculate 
Stat1 binding in the presence of the various 
phosphopeptide concentrations, the reso- 
nance signal 20 s after the end of the injection 
was monitored. Binding was calculated as the 
percentage of total Stat1 binding in the ab- 
sence of competing peptide. This data repre- 
sents the mean and standard deviation of at 
least three independent experiments. The se- 
quences of the peptides used in this study are 
represented in Table 1. 
Stat1 peptides (IDso = 7.5 t&l). The ability of Stat1 to 
interact with phosphopeptides derived from Stat3 (IDso = 
33 PM), Stat4 (IDm = 60 FM), and Stat6 (IDa = 32 PM) 
was of similar magnitude to that of the Statl-Stat1 phos- 
phopeptide interaction. However, Stat1 showed only lim- 
ited ability to bind to the Stat5 phosphopeptide (IDso = 
300 PM). None of the peptides bound to Stat1 when used in 
nonphosphorylated form (data not shown). These results 
demonstrate that the latent form of Stat1 interacts prefer- 
entially with its docking site on the phosphorylated IFNy 
receptor a chain and suggest that the Stat1 SH2 domain 
may show an ordered preference in its ability to interact 
with other phosphotylated Stat proteins. 
Dimerization of Stat1 Results in a 
High Avidlty Complex 
The current concept of Stat protein dimerization is that it 
occursas a result of the paired interactions of the phospho- 
tyrosine of one Stat with the SH2 domain of the second 
(Shuai et al., 1994; Hou et al., 1994). This model predicts 
that a Stat1 homodimer should be held together with an 
avidity that is considerably greater than that demonstrated 
by the individual SH2 domain for phosphotyrosine con- 
taining sequences of either Stat1 or the IFNy receptor. 
To evaluate this possibility, we used a cell-free Stat1 
electrophoretic mobility shift analysis (EMSA) (Igarashi et 
al., 1993; Greenlund et al., 1994) in which the IFNy recep- 
tor 436-446 phosphopeptide was added either before or 
after IFNy induced Stat1 activation. Addition of phospho- 
peptide prior to IFNy treatment inhibited Stat1 DNA bind- 
ing in a dose-dependent manner (Figure 6). In contrast, 
substantially higher concentrations of phosphopeptide 
were required for maximal inhibition of Stat1 DNA binding 
activity by preformed Stat1 homodimer, i.e., when the IFNy 
receptorderived phosphopeptide was added to cellular 
homogenates after IFNy treatment. Nonphosphorylated 
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Figure 6. Differential inhibition of Stat1 Activation and Expression of 
DNA Binding Activity by the IFNy Receptor Phosphopeptide 
Cola-205 homogenates were preincubated either in the absence 
(closed circle) or presence (open square) of IFNr receptor a chain- 
derived 466-446 phosphopeptide at concentrations of 0.046,0.24,1.2, 
6.0,30,150 pM. Homogenateswere then incubated in the presence of 
IFNy for 5 min at 37%. Extracts were prepared by adding stop buffer 
containing the IFNy receptor 466-446 phosphopeptide at concentra- 
tions that corresponded to each experimental condition. Stat1 DNA 
binding activity was assessed by EMSA using agP-labeled oligonucle- 
otide probe derived from the GRR of the FrrrRl gene promoter. Gel 
shift complexes were quantitated using a Molecular Dynamic Phos- 
phoimager and plotted as a percentage of Stat1 binding in the absence 
of phosphopeptide. 
436-444 peptide did not affect Stat1 DNA binding activity 
when added before or after IFNy treatment (data not 
shown). Moreover, Stat1 homodimers (formed by coex- 
pressing Stat1 and Jak-1 in cells) were unable to be copre- 
cipitated by biotinylated phosphotylated 436-447 IFNy re- 
ceptor peptide (data not shown). Taken together, these 
results suggest that the Stat1 homodimer is held together 
with sufficient avidity that its component SH2 domains 
are unavailable for binding external phospholigand sites. 
Thus, Stat1 homodimers that form as a result of dissocia- 
tion of phosphorylated Stat1 monomers from activated re- 
ceptor docking sites are unlikely to rebind to their receptor 
tethers. 
Discussion 
Herein we demonstrate that purified latent Stat1 binds di- 
rectly to a tyrosine-phosphorylated IFNy receptor a chain 
intracellular domain sequence that is known to play a criti- 
cal role in mediating IFNy-dependent Stat1 recruitment 
and induction of biologic responses. Using surface plas- 
mon resonance and immunoprecipitation technologies, 
we establish the affinity of the interaction between a Stat 
protein and its physiologic tyrosine-phosphorylated bind- 
ing site (KD = 137 nM), demonstrate the specificity of the 
interaction, and show that the key receptor amino acids 
that contribute most to the formation of the Stat1 docking 
site are a phosphotyrosine at position 440, an Asp at posi- 
tion 441, and a His at position 444. We show that Stat1 
displays an ordered ability to interact with other Stat pro- 
teins. Finally, we suggest that homodimerization of phos- 
phorylated monomeric Stat1 molecules that dissociate 
from closely juxtaposed receptor docking sites may be a 
mechanism that favors accumulation of activated Stat1 in 
the cytosol, thereby making it available for nuclear translo- 
cation. We propose that the interactions that occur in cy- 
tokine-treated cells between Stat proteins and their re- 
spective tyrosine-phosphorylated ligands is an ordered 
process that is governed in an affinity-driven manner. 
The affinity and characteristics (including the rapid dis- 
sociation rate) of the interaction between Stat1 and its 
phosphorylated IFNy receptor docking site are compara- 
ble to that reported for other SH2 domain-containing pro- 
teins and model high affinity phosphotyrosine-containing 
9-12 aa peptide ligands (K. = 50-l 10 nM; Panayotou et 
al., 1993; Marengere et al., 1994). Importantly, it has been 
established that 12 aa phosphopeptides are suitable 
probes for monitoring the binding affinity and specificity 
of SH2 domain interactions and that longer peptides offer 
no significant advantage (Piccione et al., 1993). One par- 
ticularly novel aspect of our current study is that instead 
of using model phosphopeptides that are selected strictly 
on the basis of SH2 domain binding affinities, we have 
employed phosphopeptide sequences that are based on 
physiologically important regions of authentic Stat1 li- 
gands. The biologic relevance of our observations is sup- 
ported by our previous biological studies. These analyses 
established that Y440 is the physiologically important sub- 
strate of the IFNy activatible tyrosine kinase(s) and be- 
comes rapidly (15 s) phosphorylated following addition of 
IFNy to cells (Greenlund et al., 1994); phosphorylated 
Y440, together with D441 and H444, are obligatorily re- 
quired for IFNy-dependent Statl-mediated signaling in 
cells (Farrar et al., 1992); and a peptide containing phos- 
phorylated Y440, D441, and H444 blocked IFNydependent 
Stat1 activation in cell homogenates (Greenlund et al., 
1994). Thus, the conclusions reached in this current report 
reflect the merger of both biochemical and biological 
data. 
Using altered phosphopeptide ligands derived from 
functionally inactive IFNy receptor a chain point mutants, 
we established that the amino acids in the receptor dock- 
ing site at positions +l and +4 relative to the phosphotyro- 
sine contribute significantly to the affinity of the Statl- 
receptor interaction. Ala substitution of either D441 or 
H444 led to a 25 to 40-fold reduction in Stat1 binding 
affinity, while Ala substitution of K442 or P443 did not sig- 
nificantly affect the affinity of Stat1 peptide binding. This 
data correlates with our previous demonstration that Ala 
substitution of D441 or H444 within the intact receptor 
a chain ablated signaling activity of the mutant receptor 
protein (Farrar et al., 1992; Greenlund et al., 1994) and 
confirms the distinct topographical orientation of the speci- 
ficity-determining residues in the Stat1 SH2 domain ligand 
compared with typical Src family SH2 domain ligand (i.e., 
the specificity-conferring residues occur at positions +l 
and +3 relative to the phosphotyrosine; Songyang et al., 
1993). Taken together, these results suggest that Stat1 
must display a minimal binding affinity to its tyrosine- 
phosphorylated substrate before Stat activation can occur 
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Figure 7. Model of Human IFNy Signal Transduction 
In an unstimulated cell, the human IFNy receptor a and 9 polypeptides carry distinct Jak kinases in inactive form (MOller et al., 1999; Watling et 
al., 1993) but are not preassociated with one another. Jak-1 constitutively associates with the receptor a chain intracellular domain (Igarashi et 
al., 1994) through an LPKS sequence (receptor residues 299-269; Greenlund et al., 1994; D. H. Kaplan and R. D. S., unpublished data). Jak-2 
constkutlvefy associates with the receptor f3 chafn by binding to a 9 chain PPSIPLGIEEYL sequence (residues 2S%274, E. A. Bach and Ft. D. S., 
unpublished data). Signal transduction through the IFNT receptor is initiated following binding of a IFNy homodimer (Ealick et al., 1991) to two 
IFNy receptor a chains, thereby inducing a chain dimerixation (Fountoulakls et al., 1992; Greenlund et al., 1993). The receptor 9 chain then 
associates with the ligand-receptor a chain complex, thereby bringing the intracellular domains of the receptor pofypeptides and the kinases that 
are associated with them into close juxtaposition. In the complex, the Jak kineses transactivate one another and the activated enzymes then 
phosphorylate the critical tyrosine 440 residues in each of the dimerizsd IFNy receptor a chain intracellular domains. This event forms on the 
dimerized receptor pofypeptides two moderately high affinity, specific, and juxtaposed docking sites for latent Statl. Stat1 molecules then bind 
directly to each phosphorylated receptor a chain via the Stat1 SH2 domains (Greenlund et al., 1994; Heim et al.. 1995) and are thereby brought 
into close proximity with the activated receptor-associated tyrosine klnases. Stat1 is subsequently activated by phosphorylation of a specific tyrosine 
residue c/701) (Shuai et al., 1992, 199Sa, 199Sb; Miller et al., 1999; Wading et al., 1993; Silvennoinen et al., 1993). The rapid dissociation of 
the Statl-receptor complexes, which are in close proximity with one another, favors the in situ formation of Stat1 homodimers, which are stabilized 
by reciprocal SH2 domain binding (Shuai et af., 1994). This event thereby releases Stat1 from its receptor tether allowing the activated complex 
to translocate to the nucleus and induce gene transcription (Shuai et al., 1992). 
and that this affinity is governed by amino acids in particu- 
lar downstream locations from the phosphotyrosine. The 
interaction of Stat1 with the tyrosine-phosphorylated Stat1 
sequence is of even lower affinity than that of the receptor 
mutants and, therefore, we predict that Stat1 is unlikely 
to be recruited by a receptor-associated tyrosine-phosphor- 
ylated Stat1 molecule. However, since the local concentra- 
tion of Stat1 at the membrane is unknown, we cannot for- 
mally rule out this possibility at the current time. 
Two additional mechanisms concerning IFNy-induced 
Stat1 activation that need to be defined are the mechanism 
underlying the exclusive generation of Stat1 homodimers 
in IFNy-treated cells and the process by which activated 
Stat1 is released from its receptor docking site. We now 
know that IFNy induces receptor a chain dimerization 
(Fountoulakff et al., 1992; Greenlund et al., 1993); activation 
of receptor-associated tyrosine kinase(s) (Miiller et al., 
1993; Watling et al., 1993); formation of juxtaposed Stat1 
docking sites on the dimerized receptor a chains (Dighe 
et al., 1993; Greenlund et al., 1994); and recruitment and 
tyrosine phosphorylation of Stat1 (Shuai et al., 1992, 
1993a; Greenlund et al., 1994). The formation of IFNy- 
induced Stat1 homodimers appears to be a reflection of 
the ligand-induced dimerization of Stat1 binding sites on 
the 1FN-r receptor a chain, an event that would bring two 
receptor-associated phosphorylated Stat1 monomers into 
close proximity with one another. The experimental sup 
port for this concept is derived from the observation that 
human or murine IFNy receptor a chains containing point 
mutations at the functionally critical Y440 (human) or Y420 
(murine) residues act as dominant-negative mutants when 
overexpressed in homologous cells (Dighe et al., 1993). 
Importantly, IFNy responsiveness can be restored in the 
inactivated cells by expressing in them the wild-type recep- 
tor. These observations thus indicate that the dominant- 
negative mutants function to prevent formation of dimer- 
ized Stat1 binding sites and are not acting by sequestering 
important components of the IFNr signaling pathway. The 
observations reported herein demonstrate that Stat1 rap 
idly and reversibly dissociates from its receptor binding 
site and that Stat1 homodimers display decreased ability 
to interact with the phosphorylated receptor docking site. 
These observations predict that once the juxtaposed phos- 
phorylated Stat1 monomers dissociate from the receptor 
they form high avidity homodimers stabilized by reciprocal 
SH2 domain-phosphotyrosine interactions and therefore 
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are unable to rebind to the receptor because they lack 
unoccupied SH2 domains. A proposed model for Stat1 
activation by the ligated IF& receptor is presented in 
Figure 7. 
In the case of cytokine receptors that produce Stat1 
containing heterodimers, a similar scenario can be envis- 
aged except that distinct binding sites for each Stat protein 
would have to be present on either unique receptor sub- 
units or on an individual receptor polypeptide. Based on 
the BlAcore binding data, it is predicted that Stat1 would 
not be recruited by receptor-associated phosphorylated 
forms of Stat3, Stat4, Stats, or Stat6 because Stat1 binds 
to these other phosphorylated ligand sites with an affinity 
that is significantly below the minimal affinity required for 
Stat1 activation. This observation explains why Stat1 is 
not activated by every cytokine receptor. However, it is of 
significant interest that Stat1 binds to the StatP-derived 
phosphopeptide with an affinity that is intermediate be- 
tween the active IFNy receptor docking site sequence and 
the inactive DAor HA mutant sequences. This observation 
predicts that IFNa receptor-associated tyrosine-phosphor- 
ylated Stat2 might act as an effective docking site for Stat1 . 
In fact, recent data utilizing mutant cell lines lacking Stat1 
or Stat2 supports this possibility. In the U3 cell line lacking 
Statl, IFNa induced the tyrosine phosphorylation of Stat2 
(Improta et al., 1994). In contrast, IFNa was unable to 
induce tyrosine phosphorylation of Stat1 in the State- 
deficient U6A cell line (Leung et al., 1995). These observa- 
tions led Leung et al. (1995) to propose that Stat2 might 
indeed serve as the adapter protein for Stat1 recruitment 
by IFNa. 
The generality of these obsenrations are supported by 
the work of three other groups as well as separate studies 
by ourselves. Hou et al. (1994) showed that a purified 
activated Stat6 homodimer could be dissociated by high 
concentrations of specific interleukin4 (IL-4) receptor in- 
tracellular domain phosphopeptides containing tyrosine 
residues 576 or 606. Although these results suggested 
that phosphotyrosine containing receptor intracellular do- 
main sequences were capable of interacting with purified 
dimeric Stat6 complexes, they were distinct from the IFNy 
receptor studies because the functional importance of the 
two tyrosine-containing IL4 receptor sequences has not 
yet been established and the phosphopeptide binding abil- 
ity of latent monomeric Stat6 was not assessed. Subse- 
quently, Stahl et al. (1995) showed that Stat3 activating 
ability could be transferred to the erythropoietin receptor 
(which does not normally support activation of Stat3) by 
transfer to the intracellular domain of the receptor of partic- 
ular tyrosine-containing sequences from the gp130 com- 
ponent of the IL-GILIFICNTF receptor family (that has been 
shown to activate Stat3). Moreover, we have recently iden- 
tified two Stat3 binding sites located in tandem in the li- 
gand-binding chain of the IL-10 receptor and have con- 
firmed their functional role in manifesting IL-l O-dependent 
cellular responses (Ft. Weber-Nordt, A. C. G., J.K. Riley, 
K. W. Moore, J. E. Darnell, Jr. and R. D. S., submitted). 
Importantly, these sequences were shown to interact with 
Stat3 but not Stat1 demonstrating Stat specificity for 
unique receptor sequences. Finally, Heim et al. (1995) 
recently demonstrated that Stat recruitment by specific 
cytokine receptors is determined by the specificity of the 
SH2 domain of the Stat protein. Replacement of the SH2 
domain of Stat2 (the family member utilized by the IFNa 
receptor but not the IFNy receptor) with the Stat1 SH2 
domain led to Stat2 activation by the IFNy receptor. 
Thus, taken together these studies establish the key 
role that tyrosine-phosphorylated cytokine receptor intra- 
cellular domain sequences play in the specific recruitment 
of particular Stat proteins. As a result of this specific and 
direct binding and the subsequent affinity-driven interac- 
tions of the recruited Stat proteins, cytokines manifest the 
ability of inducing expression of the genes that ultimately 
ExperImental Procedures 
Stat1 cDNA Prsparatlon 
The human Stat1 cDNA was cloned by pclymerase chain reaction 
using a cDNA library prepared from human Cola-205 cells. The re- 
sulting cDNA was sequenced using the Taq DyeDecxy Terminator 
Cycle sequencing kit (Applied Biosystems, Foster City, California) and 
corresponded to the published sequence (Schindler et al., 1992a). 
A 10 residue His tag was engineered onto the amino terminus of 
Stat1 by a *step polymerase chain reaction utilizing the PET 16b 
expression vector (Novagen, Madison, Wisconsin) as a template en- 
coding the His tag. The His-tagged Stat1 cDNA was subsequently 
cloned into the vaccinia virus recombination vector, PTMI, which was 
provided by Drs. R. Mercer and K. Grindstaff (Washington University 
School of Medicine, St. Louis, Missouri and Stanford University, Palo 
Alto, California, respectively) which places Stat1 under the transcrip 
tional control of the T7 promoter. 
The cDNA encoding murine Jak-1 was a gift from Dr. S. Nagata 
(Osaka Bioscience Institute, Osaka, Japan). A IO residue Hi tag was 
also engineered onto the carbcxyl terminus of Jak-1 . The Jak-1 cDNA 
was subsequently cloned into the PTM3 plasmid. 
Generation of Recombinant Stat1 Contalnlng Vacclnla Virus 
Wild-type vacciniavirus, VTF7-3 (recombinant vacclniavirus encoding 
the bacteriophage I7 RNA polymerase), and the CV-1 and BSC-40 cell 
lines were provided by Drs. R. Mercer and K. Grindstaff. Homologous 
recombination of the PTM3-Statl vector into wild-type vaccinia virus 
wasachievedbyinfectingcv-1 withwild-typevacciniavirusandsubsa 
quently transfecting into the infected cells the PTM3-Statl vector, 
as described by Earl et al. (1994). Selection and purification of the 
recombinant virus was achieved using published protocols (Earl et al., 
1994). Recombinant Jak-1 virus was plaque purified and amplified in 
a manner analogous to the recombinant Stat1 virus. 
For large scale preparation of recombinant Stat1 , BSC40 cells were 
coinfected with VTF7-3 and recombinant Stat1 vaccinia viruses and 
cultured for an additional 12 hr. Cells were removed from plates by 
scraping, pelleted by centrifugation, and resuspended to 3.3 x 10’ 
cells/ml in homogenization buffer (50 mM Tris [pH 7.51 containing 10% 
glycerol, 1 mM PMSF, IO &ml leupeptin, 10 pg/ml aprotinin, 1 mM 
Na orthovanadate, 2 mM fI-mercaptcethanol). Cells were disrupted 
by 10 strokes in a steel dounce. Sodium chloride was added to the 
homogenate at a final concentration of 150 mM, and the homogenate 
centrifuged for 10 min at 15,000 rpm in a Beckman JA-20 rotor. The 
supsrnatant was removed and the recombinant Stat1 protein purified 
using NTA Ni” Sepharose (Qiagen, Incorporated, Chatsworth, Califor- 
nia) according to the instructions of the manufacturer. Purified Stat1 
was dialyzed against 10 mM Tris (pH 6.8). 150 mM NaCI, and 0.5 
mM DTT and the protein wncentration of the final preparation was 
determined using the BioRad protein assay (BioRad, Richmond, Cali- 
fornia). Purified Stat1 (1 mg) was routinely obtained from 6 x 10 
virus-infected BSC-40 cells. The preparation was analyzed by SDS- 
PAGE (Laemmli, 1979) and Cwmassie brilliant blue R-250 (BioRad) 
staining. Western blot analysis was performed on the purified prepara- 
tion using rabbit sera directed against amino acid 2-66 of Stat1 
(29132). amino acid 598-705 of Stat1 (2991) (both of these antisera 
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were provided by Dr. C. Schindler, Columbia University, New York, 
New York), and the carboxy-terminal 36 amino acids of Stat1 as de- 
scribed previously (Greenlund et al., 1994). 
Generetion of Hamster MAba Spuclflc for Stat1 
The Statl-speciflc MAbs ATO- DB and ATO2F5 were generated in 
Armenian hamsters as previously described (Sheehan et al., 1995) 
following four immunizations with 25 ugofpurified recombinant human 
Statl. Hybridoma cultures were screened by enzyme.linked immuno- 
sorbent assay (ELISA) using immobilized recombinant Statl. ATC-2F5 
and ATG-1 D9 reacted in ELISA with full-length recombinant Stall, a 
GST fusion protein encompassing the Stat1 SH2 domain (Stat1 resi- 
dues H557-K959), but not either GST or GST fusion proteins con- 
taining other Stat1 molecular regions. These antibodies immunopre 
cipitated and Western blotted recombinant and natural latent human 
and murine Stat1 but did not react with activated dimerized Stat1 
derived from IFNy-treated cells. 
In Vitro Activation of Stat1 
Purified recombinant Stat1 (1 ug) was incubated with 1 ug of purified 
recombinant Jak-1 in buffer containing 30 mM Tris (pH 7.5), 10 mM 
MgCb, IO mM MnCb, and 200 pM ATP in a volume of 25 ul at 23OC 
for 30 min. We then subjected 14 ul of the reaction to EMSA using a 
=P-labeled oligonucleotide probe derived from the y response region 
(GRR) of the FcfRl gene promoter as previously described (Pearse 
et al., 1993; Greenlund et al., 1994). 
PeptIde Synthesis 
The synthesis of the biotinylated 439-447 lFN7 receptor a chain- 
derived phosphopeptide (TSFGY-PQDKPHVLV), the biotlnytated 
nonphosphorytated 435-447 psptide, and the blotinytated 459-499 
phosphopeptide (SLIGY-POAPTEDSK) was previously described 
(Greenlund et al., 1994). Synthesis of nonbiotinylated phoephopep- 
tides was performed on an Applied Bbsystems 432A Personal Peptide 
Synthesizer using 75 pmol FMGC-phosphotyrosine obtained from Ad- 
vanced ChemTech (Louisville, Kentucky) and a Synergy empty column 
kit (Applied Bllsystems). All other peptlde synthesis and processing 
was according to the protocol of the manufacturer. Phosphopeptides 
were analyzed and purified as described (Greenlund et al., 1994). 
Amino acid sequences of the peptides used in this study are listed in 
Table I. 
Preclpltatlon ot Stat1 with the Blotlnylated Phospho~eptldes 
Biotinylated peptide (100 nM) (439-447 peptide, 439-447 phospho- 
peptide, or 459-469 phosphopeptide) was incubated 12 hr at 4OC with 
IO nM purified recombinant Stat1 in I ml of 20 mM HEPES buffer (pH 
7.4) containing 150 mM NaCI, 0.5 mM DTT, and 0.5% NP-40. UltraLink 
immobilized Neutravidin Plus (40 ul) on 3M Emphaze Biosupport Me- 
dium AB 1 (Pierce, Rockford, Illinois) was added and the incubation 
continued for an additional 1 hr at 4OC. The biosupport was then 
washed and precipitates analyzed by SDS-PAGE and Western blot- 
ting with rabbit anti-Stat1 carboxyl terminus serum as described 
(Greenlund et al., 1994). 
In some experiments, purified Stat1 (10 nM) was pretreated for 5 
hr at 4OC with different amounts of purified anti-Stat1 ATG-2F5 MAb. 
irrelevant species-matched H22 MAb (Schreiber et al., 1995), or 15 
ul of either normal hamster sera or rabbit antisera directed against 
the carboxy-terminal 39aaof Statl. Biotinylated IFNy receptor-derived 
439-447 phosphopeptide (33 nM) was then added and the reaction 
mixtures processed as described above. 
Anslyds of Stat1 Blndlng to the IFNy Receptor a Chain 436-447 
PhoqhoPePtlde Udng Surface Plasmon Resonance 
The Pharmacia BlAcore Biosensor employs the phenomenon of sur- 
face plasmon resonance to monitor the refractive index change in a 
flow cell due to the binding of macromolecules to immobilized ligand 
(BIAcore User Manual, Phamtacia, Piscataway, New Jersey). The ac- 
cumulation of mass on the flow cell surface effects the refractive index 
of the surface, thereby effecting the intensity of the reflected light. 
Since protein mass determines the refractive index, the change in 
light intensity is directly proportional to the protein mass bound to 
ligand. 
IFNy receptor a chain biotinylated 439-447 phosphopeptide was 
immobilized on a stmptavidln sensorchip surface (SA-5, Pharmacia) 
by injecting 10 ul of 20 nM peptide in IO mM HEPES buffer (pH 7.5) 
containing 500 mM NaCl at a flow rate of 5 @/min. Pmptlde 
coupling to the sensorchip surface was monitored using the anti 
phosphotyrosine MAb, PY-20. Blotinylated forms of IFNy receptor- 
derived nonphosphorylated 435-447 peptide and phospholylated 
459-459 peptides were immobilized in a similar manner. 
To determine the equilibrium dissociatbn constant (16) describing 
the interactbn of Stat1 with the immobilized439-447 phoaphopepllde, 
purified Stat1 preparatllns at concentrattons ranging from 39-200 nM 
in 10 mM HEPES buffered physiitogic satlne @H 7.4) wntalnlng 3.4 
mM EDTA and 0.005% P-20 surfactant (Pharmacia) were injected over 
the phosphcpeptide surface at a Row rate of 3 ul/mln. The steady-state 
equilibrium response (Ftq) determined using the BlAevak&bn 2.1 
eoftware(Pharmada)~wbjectedtoScatchardan~istocalculate 
theKo.Thekinebiconandoffrateconstsntswsmcabulateduslngsulism 
plesmon msonsJlc8 blndlng data from the aeso&ton and dissociatton 
phases of the mactlon usklg the BtAevaiuatbn 2.1 softwam. 
The KD describing the interactbn of Stat1 with the soluble IFb 
receptor 439-446 phosphopeptide in solution was also determined 
using the BIAcore. Purifled Stat1 (0.5 uM) was incubated wfth the 
solubte IFNy receptor 438-448 phosphopeptlde at concentrations 
ranging from 0.019-10 pM for 30 min at 10°C. The mixtures were 
then injected over a sensorchip surface containing immobilized IFNT 
receptor a chain 435-447 phosphopepbde. The Ko was calwlated 
based on the initial binding rate of Stat1 in the presence of the various 
phosphopeptide wncentrations using the BlAevaiuation 2.1 software 
solution affinlty model (BIAwre User Manual). 
ComPetltlon Blndlng Andyda Udng tha Bkore Bloaonsor 
Stat1 (0.5 pM) was incubated with various concentrations of different 
nonbiitinylated phoephopeptides. The mixtures were then injected 
onto a sensorchip surface to whiih the bbtinylated 435-447 phoepho- 
peptlde was immobilized. To eliminate refractive index changss due 
to differences in soiutlon wmposition, a report point was monitored 
20 s after completion of the Injectbn. Stat1 binding in the presence 
of phosphopeptide was then catculated as a percentage of total Stat1 
binding in the absence of competitor. Nonspecific association was 
determined as the response (RU) in the presence of 10 PM 439-449 
phosphopeptide (less than 2% of total binding). 
lnhlbltlon ot Stat1 DNA Blndlng Actlvlty Udng 
a CoICFm Acttvatlon Assay 
Cellular homogenates were prepared from Cole-205 cells by dounce 
homogenization as prevbusly described (Greenlund et at., 1994). All 
quots (50 ul) were Incubated for 45 min on lee either in the absence 
ofpeptideorthepresenceofdllrentwncentratbnsoftheIF~recep 
tor a chain-derived 435-445 phosphopeptkie. The reactions were pre 
warmed for 2 min at 37OC, then treated with 1900 IRU of lFf+y (which 
was provided by Genentech, Incorporated. South San Fran&co, Call- 
fomia)for5mln.Stop buffer(450 ul)(Greenlundetal., 1994)wntaining 
different wncentratlons of the 438-448 phosphopeptlde was added 
to each reaction that was preincubated wtth peptide or without peptkie 
prior to IFNT treatment. Samples were vortexed 3 8, incubated on ice 
for 5 min, and subjected to centrifugation at 12,000 x g for 5 min at 
4OC. Supernatants were removed and the incubation continued an 
additional 45 min on ice. of each reaction, 14-l (5 ug) was then 
subjected to EMSA using the GRR oligonucleotide probed as de 
scribed above. Binding of Stat1 to the ollgonucleotide probe was quan- 
Mated using a Molecular Dynamics Phosphoimager (Sunnyvale, Cali- 
fornia). 
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